Idiopathic Inflammatory Myositis Market Predicted to Show Positive Growth at a Tremendous CAGR of 21.1% by 2034 | DelveInsight
The idiopathic inflammatory myositis market is set for significant growth driven by the introduction of new therapies such as dazukibart (PF 06823859), efgartigimod, SAPHNELO (anifrolumab), brepocitinib, and HIZENTRA, among others. Furthermore, the increasing number of cases, influenced by risk factors like genetic predisposition, viral infections, and UV exposure, is anticipated to further heighten the demand for effective treatments.
LAS VEGAS, Jan. 6, 2025 /PRNewswire/ -- DelveInsight's Idiopathic Inflammatory Myositis Market Insights report includes a comprehensive understanding of current treatment practices, idiopathic inflammatory myositis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Key Takeaways from the Idiopathic Inflammatory Myositis Market Report
- According to DelveInsight's analysis, the market size for idiopathic inflammatory myositis was found to be USD 447 million in the 7MM in 2023.
- As per the estimates, among the therapies currently in use, immunoglobulins held the largest market share, generating approximately USD 270.3 million in revenue in 2023 across the 7MM.
- The total diagnosed prevalent cases of idiopathic inflammatory myositis in the 7MM were approximately 191K cases in 2023, which are expected to increase during the forecast period (2020–2034).
- Leading idiopathic inflammatory myositis companies such as Pfizer, Argenx, AstraZeneca, Priovant Therapeutics, CSL Behring, Abcuro, Inc., Amgen, Janssen, Galapagos NV, Immunoforge, Merck KGaA (EMD Serono Research & Development Institute), Cabaletta Bio, Restem, and others are developing novel idiopathic inflammatory myositis drugs that can be available in the idiopathic inflammatory myositis market in the coming years.
- The promising idiopathic inflammatory myositis therapies in the pipeline include Dazukibart, Efgartigimod, SAPHNELO (Anifrolumab), Brepocitinib, HIZENTRA, Empasiprubart, Ulviprubart (ABC008), Daxdilimab, Nipocalimab, Froniglutide (PF1801), GLPG3667, Enpatoran (M5049), CABA-201, Umbilical Cord Lining Stem Cells (ULSC), and others.
- In November 2024, argenx decided to continue developing efgartigimod SC (efgartigimod alfa and hyaluronidase-qvfc) in the ongoing Phase 2/3 ALKIVIA study for adults with idiopathic inflammatory myopathies. The decision was based on topline results from the Phase 2 portion, which met the primary endpoint by demonstrating a statistically significant treatment effect in the mean total improvement score (TIS) at Week 24. Additionally, improvements were observed across all six core set measures of the TIS, favoring efgartigimod SC over placebo.
Discover which therapies are expected to grab the major idiopathic inflammatory myositis market share @ Idiopathic Inflammatory Myositis Market Report
Idiopathic Inflammatory Myositis Overview
Idiopathic inflammatory myositis (IIM) is a rare autoimmune disorder that leads to muscle inflammation, causing muscle weakness, and in some cases, skin rashes. It encompasses several conditions, including polymyositis, dermatomyositis, inclusion body myositis, and necrotizing autoimmune myopathy. The exact cause of IIM is unknown, but it is thought to be triggered by an autoimmune response where the body's immune system mistakenly attacks its own muscle tissues. Genetic, environmental, and infectious factors may contribute to the development of the condition.
Symptoms of IIM typically include progressive muscle weakness, especially in the upper arms, thighs, neck, and shoulders. Patients may also experience fatigue, difficulty swallowing (dysphagia), joint pain, and in the case of dermatomyositis, a characteristic rash. The rash can appear as red or purple discoloration over the eyelids (heliotrope rash) or a raised, scaly rash on the knuckles (Gottron's papules).
Diagnosis involves a combination of clinical examination, blood tests, muscle biopsy, and imaging studies. Blood tests often reveal elevated levels of muscle enzymes, such as creatine kinase (CK), which indicate muscle damage. Electromyography (EMG) can assess muscle electrical activity, while MRI may show muscle inflammation. In certain cases, a muscle biopsy is required to confirm the diagnosis by evaluating tissue samples for signs of inflammation and muscle damage. Identifying specific autoantibodies can also assist in diagnosis and help determine the subtype of IIM.
Idiopathic Inflammatory Myositis Epidemiology Segmentation
The idiopathic inflammatory myositis epidemiology section provides insights into the historical and current idiopathic inflammatory myositis patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The idiopathic inflammatory myositis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
- Total Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis
- Type-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory
- Gender-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory
- Age-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis
Idiopathic Inflammatory Myositis Treatment Market
Idiopathic inflammatory myositis, while classified as a rare disease, has become more widely recognized in recent years, thanks to advancements in diagnostic methods, increased awareness among healthcare professionals, and a deeper understanding of the disease. This growing recognition, along with the rising number of diagnosed cases, could fuel the IIM market growth as more patients seek treatment. The management of this condition generally involves a combination of pharmacological treatments and supportive therapies, with the main goals being to reduce inflammation, control symptoms, preserve muscle function, and prevent complications.
The treatment landscape for idiopathic inflammatory myositis has evolved to include a comprehensive approach, combining medications, physical therapy, and supportive care. First-line treatments often include high-dose corticosteroids like prednisone or ACTHAR GEL to control inflammation and immune responses. Immunosuppressants, such as methotrexate, azathioprine, and tacrolimus, are commonly used to minimize long-term steroid use.
When response to initial therapies is inadequate, biologics like rituximab may be used for targeted immune suppression. Physical therapy remains a crucial component for maintaining muscle strength and function, while additional supportive treatments like NSAIDs and sun protection help alleviate symptoms. Intravenous Immunoglobulin (IVIG) therapy, with OCTAGAM 10% approved in the US and Europe and VENOGLOBULIN-IH 5% available in Japan, is another option.
For severe, treatment-resistant cases, IV cyclophosphamide may be considered, although its use is limited due to potentially severe side effects. Treatment plans are individualized based on disease severity and patient response, striving to balance efficacy with minimizing adverse effects. There is a significant unmet need for new treatments for idiopathic inflammatory myositis, as current therapies often do not fully manage the condition.
To know more about idiopathic inflammatory myositis treatment guidelines, visit @ Idiopathic Inflammatory Myositis Management
Idiopathic Inflammatory Myositis Pipeline Therapies and Key Companies
- Dazukibart PF-06823859 (anti-beta interferon): Pfizer
- Efgartigimod: Argenx
- SAPHNELO (Anifrolumab): AstraZeneca
- Brepocitinib: Priovant Therapeutics/Pfizer
- HIZENTRA: CSL Behring
- Empasiprubart: Argenx
- Ulviprubart (ABC008): Abcuro, Inc.
- Daxdilimab: Amgen
- Nipocalimab: Janssen
- Froniglutide (PF1801): Immunoforge
- GLPG3667: Galapagos NV
- Enpatoran (M5049): Merck KGaA (EMD Serono Research & Development Institute)
- CABA-201: Cabaletta Bio
- Umbilical Cord Lining Stem Cells (ULSC): Restem
Discover more about idiopathic inflammatory myositis drugs in development @ Idiopathic Inflammatory Myositis Clinical Trials
Idiopathic Inflammatory Myositis Market Dynamics
The idiopathic inflammatory myositis market is driven by several key factors, including the increasing prevalence of autoimmune diseases and advancements in diagnostic technologies. As awareness of IIM rises, early detection and accurate diagnosis are becoming more feasible, leading to timely interventions and better patient outcomes. Additionally, the growing understanding of the underlying pathophysiology of IIM is propelling the development of targeted therapies, such as biologics and immune-modulating drugs. The demand for personalized treatments tailored to individual genetic profiles is also pushing innovation in the market.
Furthermore, the rising healthcare expenditure and improved access to specialized care contribute to the market's growth, particularly in developed regions. Finally, ongoing clinical trials and research into novel treatment options continue to fuel optimism for better management and potential cures for IIM, further accelerating the market's expansion.
Potential therapies are being investigated for the treatment of idiopathic inflammatory myositis, and it is safe to predict that the treatment space will significantly impact the idiopathic inflammatory myositis market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the idiopathic inflammatory myositis market in the 7MM.
However several factors may impede the growth of the idiopathic inflammatory myositis market. One of the primary challenges is the rarity and heterogeneous nature of IIM, which makes it difficult to diagnose and classify accurately. This complicates the development of targeted therapies and slows the recruitment of patients for clinical trials, limiting the scope for market expansion. Additionally, the lack of standardized diagnostic criteria and the complexity of managing the disease, which often involves multidisciplinary care, create barriers to effective treatment and patient outcomes.
High costs associated with specialized treatments, coupled with reimbursement issues in many regions, further restrict access to therapies. Moreover, the limited understanding of the disease pathophysiology and the lack of robust biomarkers for monitoring disease progression present additional hurdles for both research and treatment optimization. As a result, these factors collectively impede the growth potential of the IIM market, requiring ongoing innovation and policy support to overcome.
Idiopathic Inflammatory Myositis Market Report Metrics | Details |
Study Period | 2020–2034 |
Coverage | 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. |
Idiopathic Inflammatory Myositis Market CAGR | 21.1 % |
Idiopathic Inflammatory Myositis Market Size in 2023 | USD 447 Million |
Key Idiopathic Inflammatory Myositis Companies | Pfizer, Argenx, AstraZeneca, Priovant Therapeutics, CSL Behring, Abcuro, Inc., Amgen, Janssen, Galapagos NV, Immunoforge, Merck KGaA (EMD Serono Research & Development Institute), Cabaletta Bio, Restem, and others |
Key Pipeline Idiopathic Inflammatory Myositis Therapies | Dazukibart, Efgartigimod, SAPHNELO (Anifrolumab), Brepocitinib, HIZENTRA, Empasiprubart, Ulviprubart (ABC008), Daxdilimab, Nipocalimab, Froniglutide (PF1801), GLPG3667, Enpatoran (M5049), CABA-201, Umbilical Cord Lining Stem Cells (ULSC), and others |
Scope of the Idiopathic Inflammatory Myositis Market Report
- Therapeutic Assessment: Idiopathic Inflammatory Myositis current marketed and emerging therapies
- Idiopathic Inflammatory Myositis Market Dynamics: Key Market Forecast Assumptions of Emerging Idiopathic Inflammatory Myositis Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Idiopathic Inflammatory Myositis Market Access and Reimbursement
Download the report to understand which factors are driving idiopathic inflammatory myositis market trends @ Idiopathic Inflammatory Myositis Market Trends
Table of Contents
1 | Key Insights |
2 | Report Introduction |
3 | Market Overview at a Glance |
3.1 | Market Share (%) Distribution of Idiopathic Inflammatory Myositis in 2020 |
3.2 | Market Share (%) Distribution of Idiopathic Inflammatory Myositis in 2034 |
4 | Epidemiology and Market Forecast Methodology |
5 | Executive Summary |
6 | Key Events |
7 | Disease Background and Overview |
7.1 | Introduction |
7.2 | Clinical Manifestations |
7.3 | Etiology and Risk Factors |
7.4 | Pathophysiology |
7.5 | Diagnosis |
7.5.1 | Differential Diagnosis |
7.5.2 | Diagnostic Criteria |
7.5.2.1 | Bohan and Peter's Diagnostic Criteria for Polymyositis and Dermatomyositis |
7.5.3 | Diagnostic Algorithm |
7.5.4 | Diagnostic Guidelines |
7.5.4.1 | The European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile IIM: 2017 |
7.6 | Treatment |
7.6.1 | Treatment Algorithm |
7.6.2 | Treatment Guidelines |
7.6.2.1 | British Society for Rheumatology Guideline on Management of Pediatric, Adolescent, and Adult Patients with IIM |
8 | Patient Journey |
9 | Epidemiology and Patient Population |
9.1 | Key Findings |
9.2 | Assumptions and Rationale: The 7MM |
9.3 | Total Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in the 7MM |
9.4 | The US |
9.4.1 | Total Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in the US |
9.4.2 | Type-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in the US |
9.4.3 | Gender-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in the US |
9.4.4 | Age-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in the US |
9.5 | EU4 and the UK |
9.5.1 | Total Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in EU4 and the UK |
9.5.2 | Type-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in EU4 and the UK |
9.5.3 | Gender-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in EU4 and the UK |
9.5.4 | Age-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in EU4 and the UK |
9.6 | Japan |
9.6.1 | Total Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in Japan |
9.6.2 | Type-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in Japan |
9.6.3 | Gender-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in Japan |
9.6.4 | Age-specific Diagnosed Prevalent Cases of Idiopathic Inflammatory Myositis in Japan |
10 | Marketed Drugs |
10.1 | Key Cross Competition |
10.2 | OCTAGAM 10% (Intravenous Immune Globulin [Human]): Octapharma/Pfizer |
10.2.1 | Product Description |
10.2.2 | Product Profile |
10.2.3 | Regulatory Milestone |
10.2.4 | Other Developmental Activities |
10.2.5 | Clinical Trials Information |
10.2.6 | Safety and Efficacy |
10.3 | VENOGLOBULIN-IH 5% IV (Human Immunoglobulin G): Mitsubishi Tanabe Pharma |
10.3.1 | Product Description |
10.3.2 | Product Profile |
10.3.3 | Regulatory Milestone |
10.3.4 | Other Developmental Activities |
10.3.5 | Clinical Trials Information |
10.3.6 | Safety and Efficacy |
11 | Emerging Drugs |
11.1 | Key Cross Competition |
11.2 | Dazukibart PF-06823859 (anti-beta interferon): Pfizer |
11.2.1 | Drug Description |
11.2.2 | Drug Profile |
11.2.3 | Other Developmental Activities |
11.2.4 | Clinical Trials Information |
11.2.5 | Safety and Efficacy |
11.2.6 | Analyst Views |
11.3 | Efgartigimod: Argenx |
11.3.1 | Drug Description |
11.3.2 | Drug Profile |
11.3.3 | Clinical Trials Information |
11.4 | SAPHNELO (Anifrolumab): AstraZeneca |
11.4.1 | Drug Description |
11.4.2 | Drug Profile |
11.4.3 | Other Developmental Activities |
11.4.4 | Clinical Trials Information |
11.4.5 | Analyst Views |
11.5 | Brepocitinib: Priovant Therapeutics/Pfizer |
11.5.1 | Drug Description |
11.5.2 | Drug Profile |
11.5.3 | Other Developmental Activities |
11.5.4 | Clinical Trials Information |
11.5.5 | Safety and Efficacy |
11.5.6 | Analyst Views |
11.6 | HIZENTRA: CSL Behring |
11.6.1 | Drug Description |
11.6.2 | Drug Profile |
11.6.3 | Other Developmental Activities |
11.6.4 | Clinical Trials Information |
11.6.5 | Analysts' View |
11.7 | Empasiprubart: Argenx |
11.7.1 | Drug Description |
11.7.2 | Drug Profile |
11.7.3 | Clinical Trials Information |
11.8 | Ulviprubart (ABC008): Abcuro, Inc. |
11.8.1 | Drug Description |
11.8.2 | Drug Profile |
11.8.3 | Other Development Activities |
11.8.4 | Clinical Trial Information |
11.8.5 | Safety and Efficacy |
11.8.6 | Analyst Views |
11.9 | Daxdilimab: Amgen |
11.9.1 | Drug Description |
11.9.2 | Drug Profile |
11.9.3 | Other Developmental Activities |
11.9.4 | Clinical Trials Information |
11.10 | Nipocalimab: Janssen |
11.10.1 | Drug Description |
11.10.2 | Drug Profile |
11.10.3 | Other Development Activities |
11.10.4 | Clinical Trials Information |
11.11 | Froniglutide (PF1801): Immunoforge |
11.11.1 | Drug Description |
11.11.2 | Drug Profile |
11.11.3 | Other Developmental Activities |
11.11.4 | Clinical Trials Information |
11.12 | GLPG3667: Galapagos NV |
11.12.1 | Drug Description |
11.12.2 | Drug Profile |
11.12.3 | Clinical Trials Information |
11.12.4 | Safety and Efficacy |
11.13 | Enpatoran (M5049): Merck KGaA (EMD Serono Research & Development Institute) |
11.13.1 | Drug Description |
11.13.2 | Drug Profile |
11.13.3 | Clinical Trials Information |
11.14 | CABA-201: Cabaletta Bio |
11.14.1 | Drug Description |
11.14.2 | Drug Profile |
11.14.3 | Other Developmental Activities |
11.14.4 | Clinical Trials Information |
11.14.5 | Safety and Efficacy |
11.14.6 | Analyst Views |
11.15 | Umbilical Cord Lining Stem Cells (ULSC): Restem |
11.15.1 | Drug Description |
11.15.2 | Drug Profile |
11.15.3 | Clinical Trials Information |
11.15.4 | Safety and Efficacy |
12 | Idiopathic Inflammatory Myositis: Market Analysis |
12.1 | Key Findings |
12.2 | Key Market Forecast Assumptions |
12.2.1 | Cost Assumptions and Rebates |
12.2.2 | Pricing Trends |
12.2.3 | Analogue Assessment |
12.2.4 | Launch Year and Therapy Uptake |
12.3 | Market Outlook |
12.4 | Attribute Analysis |
12.5 | Total Market Size of Idiopathic Inflammatory Myositis in the 7MM |
12.6 | Total Market Size of Idiopathic Inflammatory Myositis by Therapies in the 7MM |
12.7 | Total Market Size of Idiopathic Inflammatory Myositis in the US |
12.7.1 | Total Market Size of Idiopathic Inflammatory Myositis |
12.7.2 | The Market Size of Idiopathic Inflammatory Myositis by Therapies in the US |
12.8 | Market Size of Idiopathic Inflammatory Myositis in EU4 and the UK |
12.8.1 | Total Market Size of Idiopathic Inflammatory Myositis in EU4 and the UK |
12.8.2 | The Market Size of Idiopathic Inflammatory Myositis by Therapies in EU4 and the UK |
12.9 | Market Size of Idiopathic Inflammatory Myositis in Japan |
12.9.1 | Total Market Size of Idiopathic Inflammatory Myositis in Japan |
12.9.2 | The Market Size of Idiopathic Inflammatory Myositis by Therapies in Japan |
13 | Key Opinion Leaders' Views |
14 | SWOT Analysis |
15 | Unmet Needs |
16 | Market Access and Reimbursement |
16.1 | The United States |
16.1.1 | Centre for Medicare & Medicaid Services (CMS) |
16.2 | In EU4 and the UK |
16.2.1 | Germany |
16.2.2 | France |
16.2.3 | Italy |
16.2.4 | Spain |
16.2.5 | The United Kingdom |
16.3 | Japan |
16.3.1 | MHLW |
17 | Appendix |
17.1 | Bibliography |
17.2 | Acronyms and Abbreviations |
17.3 | Report Methodology |
18 | DelveInsight Capabilities |
19 | Disclaimer |
20 | About DelveInsight |
Related Reports
Inflammatory Myositis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key inflammatory myositis companies, including CSL Behring, Immunoforge Co. Ltd., Argenx, Janssen, Abcuro, Inc., Horizon Therapeutics, Merck KGaA, Galapagos NV, Priovant Therapeutics, Roivant, Alexion Pharmaceuticals, Pfizer, Kezar Life Sciences, among others.
Myositis Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myositis companies, including GlaxoSmithKline, Corbus Pharmaceuticals, Abcuro, Inc., Orphazyme, Bristol-Myers Squibb, Kezar Life Sciences, Inc., Horizon Therapeutics, Viela Bio, Paean Biotechnology Inc., Alexion Pharmaceuticals, Janssen Biotech, CSL Behring, Pfizer, Roche, among others.
Inclusion Body Myositis Market
Inclusion Body Myositis Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key inclusion body myositis companies, including Acceleron Pharma Inc, KPI Therapeutics Inc, Milo Biotechnology LLC, Nobelpharma Co Ltd, Orphazyme ApS, Ultragenyx Pharmaceutical Inc, among others.
Inclusion Body Myositis Pipeline
Inclusion Body Myositis Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key inclusion body myositis companies, including Acceleron Pharma Inc, KPI Therapeutics Inc, Milo Biotechnology LLC, Nobelpharma Co Ltd, Orphazyme ApS, Ultragenyx Pharmaceutical Inc, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
Share this article